The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The New Antiepileptic Drugs: Scientific Review
Abstract
CONTEXT: The past decade has brought many advances to the treatment of epilepsy, including many new pharmacological agents. Primary care physicians often care for patients with epilepsy and therefore should be familiar with the new options available. OBJECTIVE: To review data regarding the efficacy and tolerability of antiepileptic drugs introduced in the past decade. DATA SOURCES: A search of the Cochrane Central Register of Controlled Trials was performed to identify all published human and English-language randomized controlled trials evaluating the efficacy and tolerability of the antiepileptic drugs that have been approved for use in the United States since 1990. Additional reports evaluating pharmacokinetic properties were identified through a MEDLINE search as well as review of article bibliographies. STUDY SELECTION AND DATA EXTRACTION: Search terms included felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide. Studies were selected if efficacy and tolerability were reported as major outcome measures. Included studies (n = 55) enrolled a minimum of 20 adult subjects and had a treatment period of at least 6 weeks. DATA SYNTHESIS: Eight new antiepileptic drugs have been approved for use in the United States in the past decade. Each new antiepileptic drug is well tolerated and demonstrates statistically significant reductions in seizure frequency over baseline. No randomized controlled trials have compared the new antiepileptic drugs with each other or against the traditional antiepileptic drugs. Although there is no evidence to suggest that the newer medications are more efficacious, several studies have demonstrated broader spectrum of activity, fewer drug interactions, and overall better tolerability of the new agents. CONCLUSIONS: New antiepileptic drugs offer many options in the treatment of epilepsy, each with unique mechanisms of action as well as adverse effect profiles. The new antiepileptic drugs are well tolerated with few adverse effects, minimal drug interactions, and a broad spectrum of activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Arky, R. A. (1994) · Cited by 2,632
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Blume, W. T., Lüders, H. O., Mizrahi, E., Tassinari, C., Van Emde Boas, W., & Engel, J. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.22001.x · Cited by 865
Prevalence of Epilepsy in Rochester, Minnesota: 1940–1980
Hauser, W. A., Annegers, J. F., & Kurland, L. T. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04675.x · Cited by 841
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615
Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 508
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00323.x · Cited by 451
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Picot, M., Baldy‐Moulinier, M., Daurès, J., Dujols, P., & Crespel, A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01579.x · Cited by 455
Vinik, A. I., Nevoret, M.-L., Casellini, C., & Parson, H. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.001 · Cited by 366
Zonisamide or Levetiracetam for Adults With Cyclic Vomiting Syndrome: A Case Series
Clouse, R. E., Sayuk, G. S., Lustman, P. J., & Prakash, C. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.004 · Cited by 74
Umbricht, A., DeFulio, A., Winstanley, E. L., Tompkins, D. A., Peirce, J., Mintzer, M. Z., Strain, E. C., & Bigelow, G. E. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.03.033 · Cited by 57
Metadata
- Authors
- LaRoche, S. M., & Helmers, S. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-02-04
- Volume
- 291
- Issue
- 5
- Pages
- 605
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2013782010
- Cited by
- 279
- References
- 67
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The New Antiepileptic Drugs: Scientific Review. https://app.cochat.ai/papers/10.1001/jama.291.5.605
- The paper
- LaRoche, S. M., & Helmers, S. L. (2004). The New Antiepileptic Drugs: Scientific Review. JAMA. https://doi.org/10.1001/jama.291.5.605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.